Search Results

Planatome, a medical device company that applies atomic-level polishing from the semiconductor industry to create advanced surgical blades that lead to better patient outcomes, announced a new study published in the Journal of Craniofacial Surgery.

City Therapeutics, one of BioSpace’s NextGen companies for 2026, was started by RNA royalty John Maraganore, former CEO of Alnylam.

After 27 deaths were reported in a group receiving its blood cancer drug, ADC Therapeutics is downsizing, implementing layoffs for about 30 workers.

Biotech Acquisition Company (NASDAQ: BIOT) (“BAC”), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, and Blade Therapeutics, Inc. (“Blade”), a biopharmaceutical company based in South San Francisco, Calif., today announced that they have mutually agreed to terminate the previously announced Agreement and Plan of Merger (the “Merger Agreement”), effective immediately.

Blade Therapeutics, Inc. announced that Wendye Robbins, M.D., president and CEO, will present at two investor conferences in March.

In addition to a high rate of deaths, ADC Therapeutics’ Zynlonta plus rituximab showed no overall survival benefit in patients with diffuse large B cell lymphoma, casting doubt on its value as a second-line treatment in this indication.

The merger between Blade Therapeutics and Biotech Acquisition Company will provide the company with $254.3 million to drive the development of cudetaxestat.